Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery: Progress and Future Perspectives

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2025 Feb 26

PMID 40005958

Authors

Paul Minges

Matthias Eder

Ann-Christin Eder

Affiliations

Soon will be listed here.

Abstract

Dual-labeled compounds that combine radiolabeling and fluorescence labeling represent a significant advancement in precision oncology. Their clinical implementation enhances patient care and outcomes by leveraging the high sensitivity of radioimaging for tumor detection and taking advantage of fluorescence-based optical visualization for surgical guidance. Non-invasive radioimaging facilitates immediate identification of both primary tumors and metastases, while fluorescence imaging assists in decision-making during surgery by offering a spatial distinction between malignant and non-malignant tissue. These advancements hold promise for enhancing patient outcomes and personalization of cancer treatment. The development of dual-labeled molecular probes targeting various cancer biomarkers is crucial in addressing the heterogeneity inherent in cancer pathology and recent studies had already demonstrated the impact of dual-labeled compounds in surgical decision-making (NCT03699332, NCT03407781). This review focuses on the development and application of small dual-labeled peptides in the imaging and treatment of various cancer types. It summarizes the biomarkers targeted to date, tracing their development from initial discovery to the latest advancements in peptidomimetics. Through comprehensive analysis of recent preclinical and clinical studies, the review demonstrates the potential of these dual-labeled peptides to improve tumor detection, localization, and resection. Additionally, it highlights the evolving landscape of dual-modality imaging, emphasizing its critical role in advancing personalized and effective cancer therapy. This synthesis of current research underscores the promise of dual-labeled peptides in enhancing diagnostic accuracy and therapeutic outcomes in oncology.

References

Liu S, Lin T, Li D, Leamer L, Shan H, Li Z . Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: facile generation of positron emission tomography/fluorescence dual modality agents for tumor imaging. Theranostics. 2013; 3(3):181-9. PMC: 3590587. DOI: 10.7150/thno.5984. View

Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G . Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022; 7(1):48. PMC: 8844085. DOI: 10.1038/s41392-022-00904-4. View

Kedrzycki M, Chon H, Leiloglou M, Chalau V, Leff D, Elson D . Fluorescence guided surgery imaging systems for breast cancer identification: a systematic review. J Biomed Opt. 2024; 29(3):030901. PMC: 10911048. DOI: 10.1117/1.JBO.29.3.030901. View

Verhoeven M, Handula M, van den Brink L, de Ridder C, Stuurman D, Seimbille Y . Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging. Cancers (Basel). 2023; 15(7). PMC: 10093582. DOI: 10.3390/cancers15072161. View

Unterrainer L, Calais J, Bander N . Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. Annu Rev Med. 2024; 75:49-66. DOI: 10.1146/annurev-med-081522-031439. View

Young J, Hua X, Somsel H, Reichart F, Kessler H, Spatz J . Integrin Subtypes and Nanoscale Ligand Presentation Influence Drug Sensitivity in Cancer Cells. Nano Lett. 2020; 20(2):1183-1191. PMC: 7020138. DOI: 10.1021/acs.nanolett.9b04607. View

Derks Y, Rijpkema M, Amatdjais-Groenen H, Loeff C, de Roode K, Kip A . Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer. Bioconjug Chem. 2021; 33(1):194-205. PMC: 8778659. DOI: 10.1021/acs.bioconjchem.1c00537. View

Al Olayan A, Al Hussaini H, Jazieh A . The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. J Infect Public Health. 2012; 5 Suppl 1:S50-60. DOI: 10.1016/j.jiph.2012.09.004. View

Flores D, Meurer L, Uberti A, Macedo B, Lenz G, Brunetto A . Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010; 82(1-2):95-8. DOI: 10.1016/j.brainresbull.2010.02.014. View

10.

Parsi M, Desai M, Desai D, Singhal S, Khandwala P, Potdar R . PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol. 2021; 38(8):89. DOI: 10.1007/s12032-021-01537-3. View

11.

Deng H, Wang H, Wang M, Li Z, Wu Z . Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor. Mol Pharm. 2015; 12(8):3054-61. PMC: 5460915. DOI: 10.1021/acs.molpharmaceut.5b00325. View

12.

Watson J, Juergens D, Bennett N, Trippe B, Yim J, Eisenach H . De novo design of protein structure and function with RFdiffusion. Nature. 2023; 620(7976):1089-1100. PMC: 10468394. DOI: 10.1038/s41586-023-06415-8. View

13.

Hennrich U, Eder M . [Lu]Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022; 15(10). PMC: 9608311. DOI: 10.3390/ph15101292. View

14.

Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D . Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. J Nucl Med. 2018; 60(1):71-78. PMC: 6354225. DOI: 10.2967/jnumed.118.212720. View

15.

Li Z, Lin T, Liu S, Huang C, Hudnall T, Gabbai F . Rapid aqueous [18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun (Camb). 2011; 47(33):9324-6. DOI: 10.1039/c1cc13089g. View

16.

Roy S, Bag N, Bardhan S, Hasan I, Guo B . Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics. Adv Drug Deliv Rev. 2023; 197:114821. DOI: 10.1016/j.addr.2023.114821. View

17.

Dalm S, Bakker I, de Blois E, Doeswijk G, Konijnenberg M, Orlandi F . 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2016; 58(2):293-299. DOI: 10.2967/jnumed.116.176636. View

18.

Carey K, Garton A, Romero M, Kahler J, Thomson S, Ross S . Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006; 66(16):8163-71. DOI: 10.1158/0008-5472.CAN-06-0453. View

19.

Wang M, Liu J, Xia M, Yin L, Zhang L, Liu X . Peptide-drug conjugates: A new paradigm for targeted cancer therapy. Eur J Med Chem. 2024; 265:116119. DOI: 10.1016/j.ejmech.2023.116119. View

20.

Eder A, Schafer M, Schmidt J, Bauder-Wust U, Roscher M, Leotta K . Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules. J Nucl Med. 2021; 62(10):1461-1467. PMC: 8724895. DOI: 10.2967/jnumed.120.248443. View